Clinical background:
Emicizumab (Hemlibra) is a bispecific monoclonal antibody used for the prophylaxis of bleeds in patients with Haemophilia A. Emicizumab works by bridging activated Factor IX and Factor X to restore the function of the missing activated Factor VIII. The Emicizumab assay is a modified one-stage APTT based assay used to determine plasma levels of the Emicizumab.
Specimen container paediatric:
Light blue – sodium citrate
Specimen container adult:
Light blue – sodium citrate
Minimum volume paediatric:
1.3 ml
Minimum volume adult:
2.7ml
Special requirements:
Tube must be correctly filled to line, to ensure correct ratio of blood to anticoagulant, ensure adequate mixing.
Sample Stability:
4 hrs
Transport requirements:
Samples should be transported to lab without delay
Freq Analysis:
On request
Add On Test:
[email protected] (external)
Quality Assurance:
UK NEQAS Emicizumab Supplementary Assay
Reference Ranges:
The expected on treatment levels after the patient has moved onto the maintenance dose (fortnightly injection) is in the range 40 – 60 µg/mL (Manufacturer data)